Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

A Generic Double Whammy: Teva Pharmaceutical Industries Ltd (TEVA), Mylan Inc. (MYL)

Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) saw revenue fall 8% in the fourth quarter from a generic double whammy.

Its narcolepsy drug Provigil saw generic competition from Par Pharmaceutical Companies, Inc. (NYSE:PRX) and Mylan Inc. (NASDAQ:MYL), causing sales of the branded drug to drop to $25 million in the fourth quarter from $350 million in the year-ago quarter .

And year-over-year comparison of sales from Teva’s generic drugs were hurt by last year’s stellar quarter when it benefited from U.S. launches of generic versions of Eli Lilly & Co. (NYSE:LLY)‘s Zyprexa and Pfizer Inc. (NYSE:PFE)‘s Lipitor. Generic sales in the U.S. were down 17% year over year.

Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA)Note that decreasing sales of generic versions of Zyprexa and Lipitor doesn’t actually help Lilly and Pfizer. Teva’s lower sales are due to increases in the number of companies selling the generics, which hurts Lilly and Pfizer as well.

Speaking of competition, investors should be worried about Teva’s multiple sclerosis drug Copaxone. The drug, which made up 20% of Teva’s revenue and a larger percentage of the company’s earnings, will likely see competition from Biogen Idec Inc. (NASDAQ:BIIB)‘s oral multiple sclerosis drug Tecfidera. The Food and Drug Administration is expected to approve the drug shortly.

Teva plans to submit an application with the FDA to establish a recommended dose of three times per week for Copaxone. While three injections is less than seven, it’s still more than zero, the number of injections required for oral Tecfidera.

It seems inevitable that Biogen will cut into Copaxone sales, although don’t expect a mad exodus from Copaxone when Tecfidera is launched. Like many new drugs that just offer incremental increases, doctors will likely try it on a few patients before making it a staple in their medicine bag.

It’s hard to get excited about a ho-hum quarter and the potential for declining sales of its most important branded drug. About the only thing keeping investors interest right now is that the company increased its dividend by 15%. At 3.2% yield, investors are at least getting paid a little to be patient and wait out any downturn.

The article A Generic Double Whammy originally appeared on Fool.com and is written by Brian Orelli.

Fool contributor Brian Orelli has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Loading...